Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  D. Montgomery Bissell, M.D.
D. Montgomery Bissell, M.D.

D. Montgomery Bissell, M.D.

Professor of Medicine
Department of Medicine
Director Emeritus, UCSF Liver Center

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 476-2777
Fax: 415-476-0659
Open Popup
  • Harvard College, Cambridge, MA, A.B., 1962, English
  • Harvard Medical School, Boston, MA, M.D., 1967, Medicine
  • Harvard Medical Service, Boston City Hospital, Residency training, 1967-70, Internal Medicine
  • University of California, San Francisco, Research training, 1970-73, Liver Biology
  • American Board of Internal Medicine
  • UCSF Liver Center
  • Member, UCSF Biomedical Sciences Graduate Program (BMS)
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Alcoholic Liver Disease
  • Autoimmune Hepatitis
  • Benign Liver Tumors
  • Cirrhosis
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Live Donor Liver Transplantation
  • Liver Transplantation
  • Nonalcoholic Fatty Liver Disease
  • Primary Biliary Cirrhosis
  • Primary Sclerosing Cholangitis
  • Liver Injury and Repair

Dr. D. Montgomery Bissell is Professor of Medicine and Director Emeritus of the UCSF Liver Center, an NIH-funded consortium of 40 independently funded researchers who study the liver and its diseases. Bissell has a career-long interest in liver disease, dating to when he conducted a project on hepatocellular carcinoma in East Africa as a Harvard medical student. He then turned his attention to defining the cellular responses and molecular regulation of the scarring process known as fibrosis and cirrhosis. The latter is the most important consequence of many chronic liver diseases including inborn errors of metabolism, viral hepatitis, autoimmune states, alcohol abuse and others. It also is the setting for most cases of liver cancer.

Since 1981, Bissell has led the Rice-Liver Center Laboratory at San Francisco General Hospital, known internationally for basic research on fibrosis and defining new therapies to block fibrosis progression in patients. He is a member of several professional organizations including the American Society for Clinical Investigation and the Association of American Physicians and has served on numerous review panels for NIH, the Veterans Administration and other groups.

  • Distinguished Achievement Award, American Association for the Study of Liver Diseases, 2004
  • MERIT award, NIDDK/NIH, 1998-2004
  • Advisory Council, NIDDK/NIH, 1997-2001
  • President, American Association for the Study of Liver Diseases, 1994-1995
  • Member, American Society for Clinical Investigation, 1977---

My laboratory investigates tissue remodeling in liver injury. We have been focusing recently on oval cells, which are liver progenitor cells and proliferate in several forms of liver injury. Oval cells, can be isolated and, with expansion in culture, hold promise for cell-based therapy of a variety of liver diseases. We have recently defined a member of the TNF-alpha family of cytokines that appears to be a specific growth factor for a subset of oval cells. We are interested also in mechanisms of the fibrotic response to biliary injury. We have found that TGFβ and the integrin αvβ6 have key roles.

Most recent publications from a total of 43
  1. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB, Garg P, Vaishnaw A, Simon AR, Anderson KE. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019 02 07; 380(6):549-558. View in PubMed
  2. Wang B, Balwani M, Bonkovsky HL, Anderson KE, Bloomer JR, Bissell DM, Phillips JD, Desnick RJ. Reply. Hepatology. 2018 02; 67(2):803-804. View in PubMed
  3. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 11 23; 377(21):2101. View in PubMed
  4. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 Aug 31; 377(9):862-872. View in PubMed
  5. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015 Jul 02; 373(1):48-59. View in PubMed
  6. Bissell DM, Wang B. Acute Hepatic Porphyria. J Clin Transl Hepatol. 2015 Mar; 3(1):17-26. View in PubMed
  7. Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015 Mar; 128(3):313-7. View in PubMed
  8. Bissell DM. Therapy for hepatic fibrosis: revisiting the preclinical models. Clin Res Hepatol Gastroenterol. 2011 Sep; 35(8-9):521-5. View in PubMed
  9. Bissell DM. Inflammation and hepatic fibrosis. Semin Liver Dis. 2010 Aug; 30(3):211-4. View in PubMed
  10. Bissell DM. Of mentors, mentoring, and extracellular matrix. Hepatology. 2009 Nov; 50(5):1330-8. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of D. Montgomery Bissell, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.


Site Directory